ArticleHepatology communications2025
Carbon-ion radiotherapy achieves outcomes equivalent to surgical resection for hepatocellular carcinoma.
Article in Hepatology communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study aimed to compare the clinical outcomes of carbon-ion radiotherapy (CIRT) to those of surgical resection (SR) in patients with HCC.
methodsThis retrospective study included 116 and 947 patients initially receiving CIRT and SR in Japanese institutions from September 2010 and June 2022. We used inverse probability of treatment weighting (IPTW) analysis to correct for imbalances in baseline patient characteristics between the 2 groups.
resultsThe median observation period was 3.3 years (IQR: 1.4-5.8) in the SR group and 2.8 years (IQR: 1.6-4.5) in the CIRT group (p=0.2). Before IPTW analysis, the median recurrence-free survival (RFS) was 2.3 years in the SR group and 2.2 years in the CIRT group, with no statistical significance (p=0.3). After IPTW analysis, the median RFS was 2.5 years in the SR group and 2.3 years in the CIRT group, which remained statistically nonsignificant (p=0.9). The median overall survival (OS) was not reached in the SR group, while it was 7.4 years in the CIRT group. The SR group demonstrated better survival compared to the CIRT group (p=0.02). In the IPTW cohort, the median OS was not reached in the SR group, while it remained 7.4 years in the CIRT group, showing no significant difference (p=0.4). Multivariate analyses showed that treatment choice (SR vs. CIRT) was not identified as a predictive factor for both RFS and OS.
conclusionsCIRT showed no statistically significant differences in RFS or OS compared with SR, suggesting its potential as a curative treatment option for early-stage HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.